Nkarta (NKTX) Cash from Operations (2019 - 2026)
Nkarta's quarterly Cash from Operations came in at 28199000.0 in Q1 2026, up 4.77% year-on-year from 26914707.11 in Q1 2025, and down 30.27% quarter-over-quarter from 21647000.0 in Q4 2025.
Nkarta has reported Cash from Operations for 8 years, with the latest figure at 28199000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 4.77% year-over-year to 28199000.0; the trailing twelve-month figure through Mar 2026 stood at 87286000.0 (up 13.41% YoY), and the FY2025 full-year result was 88699000.0, up 11.03% from the prior year.
- Cash from Operations for Q1 2026 stood at 28199000.0, down from 21647000.0 in the prior quarter.
- The five-year high for Cash from Operations was 7331000.0 in Q4 2022, with the low at 29612000.0 in Q1 2025.
- Average Cash from Operations over 5 years is 21162000.0, with a median of 21647000.0 recorded in 2025.
- Year-over-year, Cash from Operations surged 58.28% in 2022 and tumbled 218.56% in 2023.
- Tracing NKTX's Cash from Operations over 5 years: stood at 7331000.0 in 2022, then plunged by 218.56% to 23354000.0 in 2023, then retreated by 5.98% to 24751000.0 in 2024, then gained by 12.54% to 21647000.0 in 2025, then sank by 30.27% to 28199000.0 in 2026.
- The last three Cash from Operations figures came in at 28199000.0 (Q1 2026), 21647000.0 (Q4 2025), and 18687000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -28.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.20 Mn |
| Mar 31, 2026 | -28.20 Mn |
| Dec 31, 2025 | -21.65 Mn |
| Dec 31, 2025 | -21.65 Mn |
| Sep 30, 2025 | -18.69 Mn |
| Sep 30, 2025 | -18.69 Mn |
| Jun 30, 2025 | -18.75 Mn |
| Jun 30, 2025 | -18.75 Mn |
| Mar 31, 2025 | -29.61 Mn |
| Mar 31, 2025 | -29.61 Mn |
| Dec 31, 2024 | -24.75 Mn |
| Dec 31, 2024 | -24.75 Mn |
| Sep 30, 2024 | -24.55 Mn |
| Sep 30, 2024 | -24.55 Mn |
| Jun 30, 2024 | -21.89 Mn |
| Jun 30, 2024 | -21.89 Mn |
| Mar 31, 2024 | -28.51 Mn |
| Mar 31, 2024 | -28.51 Mn |
| Dec 31, 2023 | -23.35 Mn |
| Dec 31, 2023 | -23.35 Mn |
| Sep 30, 2023 | -20.28 Mn |
| Sep 30, 2023 | -20.28 Mn |
| Jun 30, 2023 | -21.77 Mn |
| Jun 30, 2023 | -21.77 Mn |
| Mar 31, 2023 | -20.76 Mn |
| Mar 31, 2023 | -20.76 Mn |
| Dec 31, 2022 | -7.33 Mn |
| Dec 31, 2022 | -7.33 Mn |
| Sep 30, 2022 | -14.80 Mn |
| Sep 30, 2022 | -14.80 Mn |
| Jun 30, 2022 | -16.61 Mn |
| Jun 30, 2022 | -16.61 Mn |
| Mar 31, 2022 | -18.26 Mn |
| Mar 31, 2022 | -18.26 Mn |
| Dec 31, 2021 | -17.57 Mn |
| Dec 31, 2021 | -17.57 Mn |
| Sep 30, 2021 | -18.26 Mn |
| Sep 30, 2021 | -18.26 Mn |
| Jun 30, 2021 | -17.45 Mn |
| Jun 30, 2021 | -17.45 Mn |
| Mar 31, 2021 | -14.65 Mn |
| Mar 31, 2021 | -14.65 Mn |
| Dec 31, 2020 | -12.85 Mn |
| Dec 31, 2020 | -12.85 Mn |
| Sep 30, 2020 | -12.12 Mn |
| Sep 30, 2020 | -12.12 Mn |
| Jun 30, 2020 | -10.24 Mn |
| Jun 30, 2020 | -10.24 Mn |
| Mar 31, 2020 | -8.29 Mn |
| Mar 31, 2020 | -8.29 Mn |
| Dec 31, 2019 | -6.64 Mn |
| Dec 31, 2019 | -6.64 Mn |
| Sep 30, 2019 | -4.65 Mn |
| Sep 30, 2019 | -4.65 Mn |